Aquablation therapy for BPH: what the evidence shows
Quick answer
Aquablation therapy uses a robotically-controlled waterjet guided by transrectal ultrasound to ablate BPH tissue without thermal energy. The WATER II randomized controlled trial demonstrated non-inferiority to TURP for symptom relief while showing significantly lower ejaculatory dysfunction rates, but also higher rates of post-operative transfusion. It is FDA-cleared and generally indicated for prostates in the 30-80 mL range, though evidence for larger glands is still accumulating.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @green.health.2 actually say?
The creator described aquablation therapy as a "new advanced treatment" for BPH that uses "a powerful stream of water, yes, just water" to remove prostate tissue, guided by real-time imaging. They claimed it causes "fewer side effects, especially for sexual or urinary function," takes under an hour, and has patients recovering in days. The framing is optimistic, almost promotional, but it's worth asking: does the evidence actually support this level of enthusiasm, or is this a 3D animation dressed up as settled science?
The core claims here are about mechanism, procedure time, safety profile, and recovery speed. Let's take them apart one by one.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 3 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Aquablation therapy for BPH: what the evidence shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Aquablation therapy for BPH: what the evidence shows should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Aquablation therapy uses a robotically-controlled waterjet guided by transrectal ultrasound to ablate BPH tissue without thermal energy.
FormBlends verdict
Aquablation therapy uses a robotically-controlled waterjet guided by transrectal ultrasound to ablate BPH tissue without thermal energy. The WATER II randomized controlled trial demonstrated non-inferiority to TURP for symptom relief while showing significantly lower ejaculatory dysfunction rates, but also higher rates of post-operative transfusion. It is FDA-cleared and generally indicated for prostates in the 30-80 mL range, though evidence for larger glands is still accumulating.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Aquablation therapy uses a robotically-controlled waterjet guided by transrectal ultrasound to ablate BPH tissue without thermal energy. The WATER II randomized controlled trial demonstrated non-inferiority to TURP for symptom relief while showing significantly lower ejaculatory dysfunction rates, but also higher rates of post-operative transfusion. It is FDA-cleared and generally indicated for prostates in the 30-80 mL range, though evidence for larger glands is still accumulating.
- The WATER II trial (Gilling et al., 2019, BJU International) confirmed aquablation is non-inferior to TURP for BPH symptom relief at 6 months in a randomized controlled design.
- Aquablation showed roughly 10% ejaculatory dysfunction versus 36% for TURP in WATER II, a real and meaningful difference for men who prioritize sexual function preservation.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The WATER II trial (Gilling et al., 2019, BJU International) confirmed aquablation is non-inferior to TURP for BPH symptom relief at 6 months in a randomized controlled design.
- Aquablation showed roughly 10% ejaculatory dysfunction versus 36% for TURP in WATER II, a real and meaningful difference for men who prioritize sexual function preservation.
- Post-operative transfusion rates were approximately 17% for aquablation versus 4% for TURP in the same trial, a risk the video does not mention at all.
- Most published efficacy data covers prostates in the 30-80 mL range. Evidence for very large prostates is still developing, and patient selection matters significantly.
- Aquablation requires general or spinal anesthesia, a robotic delivery system, and a trained surgical team. Describing it as 'nothing but water and precision' understates the procedure's complexity.
- A Bhojani et al. 2022 multicenter analysis in European Urology supported real-world outcomes consistent with trial data, which is a good sign for generalizability, but also confirmed the bleeding risk pattern.
- BPH treatment decisions involve real trade-offs between bleeding risk, sexual function, symptom relief, and surgeon experience. No single procedure is right for every patient, and a urology consultation is required.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
green.health.2 · TikTok creator
480.4K views on this video
Aquablation Therapy For Enalrged Prostate Treatment! (3D Animation) #enlargedprostate #bph #benignprostatichyperplasia #benignprostatichyperplasiatrea
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by green.health.2, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.